FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2402-2403 May 29, 2008 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Camilleri, M. PubMed Citation

In this issue of the Journal, Camilleri et al.¹ report on their 12-week randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of prucalopride in the treatment of chronic constipation (ClinicalTrials.gov number, NCT00483886 [ClinicalTrials.gov] ). The authors clearly document the efficacy of prucalopride in improving bowel function and quality of life in the 411 patients who received the drug, as compared with 209 patients who received placebo.

However, there is concern about a potential cardiac risk associated with this constipation-reducing drug. Prucalopride is a prokinetic 5-hydroxytryptamine₄ (5-HT₄) receptor agonist similar in function to cisapride and tegaserod, two constipation-reducing drugs . . . [Full Text of this Article]

Source Information

From the Heart Research Follow-up Program of the Cardiology Division, Department of Medicine, University of Rochester School of Medicine & Dentistry, Rochester, NY.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.